Solicitudes de Patente publicadas en los últimos 30 días / Patent Applications published in the last 30 days
Nº publicación: EP3072964A1 28/09/2016
NAT CT FOR CHILD HEALTH AND DEV [JP]
NAT CANCER CT [JP]
LSIP LLC [JP]
The present invention addresses the problem of: identifying a mutation that can serve as an indicator for predicting the efficacy of treatment using a drug in a cancer such as leukemia; providing a means for detecting said mutation; providing a means for identifying, on the basis of said mutation, cancer patients or subjects at risk of cancer in whom a drug that targets a gene having said mutation or a protein coded by same will produce therapeutic effects; etc. A method for detecting a gene fusion, which is the mutation responsible for a cancer (driver mutation), the method comprising a step for detecting ATF7IP-PDGFRB fused polynucleotide or a polypeptide coded by same in an isolated sample derived from a subject.
Nº publicación: EP3072511A1 28/09/2016
CT BADAN MOLEKULAR I MAKRO [PL]
The invention relates to the medical use of 3-aryl-1-indanones for the production of medicaments used in the anti-cancer therapies, acting selectively, against cancer cells of cervical cancer HeLa or cancer cells of chronic myelogenous leukemia K562.
Nº publicación: US2016272720A1 22/09/2016
MEMORIAL SLOAN-KETTERING CANCER CENTER [US]
Provided are compositions and methods for the treatment of hematological conditions, in particular CD99+ acute myelogenous leukemias (AML) and myelodysplastic syndromes (MDS), which comprise one or more antibody that (a) binds to the extracellular domain of CD99, (b) ligates AML and/or MDS cell-surface expressed CD99, (c) promotes the capping/clustering/aggregation AML and/or MDS cell-surface expressed CD99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated CD99+ AML and/or MDS cells. Disclosed methods include methods for identifying AML and MDS patients that are susceptible to treatment with an anti-CD99 antibody by detecting the elevated expression of CD99 in a tissue sample or cell from an AML or MDS patient and for treating an AML and/or MDS patient exhibiting elevated CD99 gene and or cell-surface protein expression by administering a composition comprising an anti-CD99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and an AML and/or MDS chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5-azacytidine, and decitabine.
Nº publicación: US2016271133A1 22/09/2016
PROLEXYS PHARMACEUTICALS INC [US]
Erastin analogs are useful in treating various cancers, particularly multiple multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.
Nº publicación: US2016272579A1 22/09/2016
DANA-FARBER CANCER INST INC [US]
THE GENERAL HOSPITAL CORP [US]
The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Nº publicación: WO2016146516A1 22/09/2016
LEON-NANODRUGS GMBH [DE]
The present invention provides nanoparticles comprising at least one boronic acid compound and at least one stabilizing agent for the at least one boronic acid compound and/or a reaction product of the at least one boronic acid compound and the at least one stabilizing agent, whereby the nanoparticles have a particle size of about 10 to about 1000 nm. The present invention also provides a pharmaceutical composition comprising these nanoparticles and a method for the preparation of these nanoparticlesand the respective pharmaceutical compositions.In addition, the present invention provides nanoparticles and pharmaceutical compositions for the treatment of several disorders, especially multiple myeloma, preferably by parenteral administration.
Nº publicación: WO2016149682A2 22/09/2016
MEMORIAL SLOAN-KETTERING CANCER CENTER [US]
Provided are compositions and methods for the treatment of hematological conditions, in particular haematopoietic and lymphoid malignancies including CD99+ acute myelogenous leukemias (AML), myelodysplasia syndromes (MDS) and T-cell neoplasms, which comprise one or more antibody that (a) binds to the extracellular domain of CD99, (b) ligates myeloid or lymphoid malignant cell-surface expressed CD99, (c) promotes the capping/clustering/aggregation myeloid or lymphoid malignant cell-surface expressed CD99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated CD99+ myeloid or lymphoid malignant cells. Disclosed methods include methods for identifying patients afflicted with a haematopoietic or lymphoid malignancy that are susceptible to treatment with an anti- CD99 antibody by detecting the elevated expression of CD99 in a tissue sample or myeloid or lymphoid malignant cell from a patient and for treating a patient afflicted with a haematopoietic or lymphoid malignancy exhibiting elevated CD99 gene and or cell-surface protein expression by administering a composition comprising an anti-CD99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and a chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5- azacytidine, and decitabine.
Nº publicación: WO2016148081A1 22/09/2016
METROPOLITAN RES CENTER FOR BLOOD DISORDERS [JP]
The present invention relates to a novel means for treating myelodysplastic syndromes, aplastic anemia or acute leukemia, characterized by comprising a combination of an adrenal corticosteroid and clarithromycin. More specifically, the present invention relates to a pharmaceutical composition for treating myelodysplastic syndromes or the like, characterized by comprising a relatively low dose of prednisolone and a relatively low dose of clarithromycin which are administered in combination.
Nº publicación: WO2016149542A1 22/09/2016
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
The invention relates generally to methods for diagnosis and treatment of follicular lymphoma or diffuse large B cell lymphoma. Specifically, the invention relates to detecting a lysine (K)-specific methyltransferase 2D (KMT2D) alteration to diagnose or treat follicular lymphoma or diffuse large B cell lymphoma.
Nº publicación: WO2016149160A1 22/09/2016
SUNSHINE LAKE PHARMA CO LTD [CN]
CALITOR SCIENCES LLC [US]
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
Nº publicación: WO2016145298A1 15/09/2016
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The present invention provides compositions, methods, and kits comprising one or more RORγ inhibitors, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma, and glioma.
Nº publicación: AU2015226976A1 15/09/2016
HACKENSACK UNIVERSITY MEDICAL CT
The described invention comprises methods for predicting recurrence of Hodgkin Lymphoma (HL) and poor clinical outcome in a Hodgkin Lymphoma (HL) subject. The methods comprise providing a sample from the HL subject and a sample from a good clinical outcome control subject; isolating total RNA comprising Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) RNA from the sample from the HL subject and from the sample from the good clinical outcome control subject; amplifying the total RNA; measuring a level of expression of the FGF2 and the SDC1 RNA in the HL subject and in the good clinical outcome control subject; and comparing the level of expression of the FGF2 and the SDC1 RNA expressed by the HL subject with the level of expression of the FGF2 and the SDC1 RNA expressed by the good clinical outcome control subject. An increased level of expression of the FGF2 RNA and the SDC1 RNA expressed by the HL subject compared to the level of expression of the FGF2 RNA and the SDC1 RNA expressed by the good clinical outcome control subject is indicative of recurrence of HL or poor clinical outcome for the HL subject. The described invention further comprises a method of detecting evidence of metastatic Hodgkin lymphoma in a Hodgkin Lymphoma (HL) subject by measuring an increased level of expression of CD30, FGF2 and SDC1 RNA in an HL subject compared to a good clinical outcome control subject.
Nº publicación: WO2016141492A1 15/09/2016
UNIVERSIT\u00C9 DE MONTR\u00C9AL [CA]
RSEM LTD PARTNERSHIP [CA]
Genes exhibiting specific mutational and/or transcriptional patterns in mixed-lineage leukemia- rearranged acute myeloid leukemia (MLL leukemia) relative to other types of AMLs are disclosed. The use of these mutational and/or transcriptional patterns for the diagnosis, prognosis, characterization and/or treatment of MLL leukemia is also disclosed.
Nº publicación: WO2016144642A1 15/09/2016
CHROMOLOGIC LLC [US]
In some embodiments of the present invention, an erythroleukemic cell includes exogenous expression of at least one selected from the group consisting of Duffy antigen receptor chemokine (DARC), glycophorin A (GlyA), basigin, beta-globin, alpha-globin, and B-cell lymphoma/leukemia 11A (BCL11A). In some embodiments of the present invention, a cell culture includes an erythroleukemic cell, including exogenous or endogenous expression of at least one selected from the group consisting of Ourfy antigen receptor chemokine (DARC), glycophorin A (GlyA), basigin, beta-globin, alpha-globin, and B-cell lymphoma/leukemia 11A (BCL11A); and hemin. In some embodiments, the cell culture also includes JQ1 and TGFβ1. In some embodiments of the present invention, a method of inducing hemoglobinization and differentiation in an erythroleukemic cell.
Nº publicación: US2016263089A1 15/09/2016
UNIV CASE WESTERN RESERVE [US]
The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
Nº publicación: US2016263095A1 15/09/2016
CELGENE CORP [US]
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Nº publicación: US2016263138A1 15/09/2016
THEAPRIN PHARMACEUTICALS INC [US]
A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.
Nº publicación: US2016263244A1 15/09/2016
RUTGERS THE STATE UNIV OF NEW JERSEY [US]
UNIV GEORGETOWN [US]
The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.
Nº publicación: WO2016142814A1 15/09/2016
SIGMA-TAU RES SWITZERLAND S A [CH]
THE UAB RES FOUND [US]
The present invention relates to roneparstat for use in a combined therapy for the treatment of multiple myeloma. In particular it has unexpectedly been found that the combined use of roneparstat with a proteasome inhibitor, in particular selected between bortezomib and carfilzomib or with melphalan improve efficacy in decreasing the overall tumor burden, especially showing synergism, with respect to the administration of each active ingredient alone.
Nº publicación: HK1215790A1 15/09/2016
BIOKINE THERAPEUTICS LTD [IL]
There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent.
Nº publicación: WO2016143896A1 15/09/2016
The present invention provides a therapeutic composition for intractable leukemia which comprises a drug (a) and a drug (b), wherein the drug (a) is a compound represented by formula (I) (wherein Ar1 represents a substituted or unsubstituted arylene group; Ar2 represents a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group; L represents an oxygen atom, -NHCO- or -CONH-; X1 represents CH; X2 and X3 represent CH and a nitrogen atom, respectively; Y represents an ethylene group; m represents 0; and Z1 and Z2 include X3 and independently represent a substituted or unsubstituted monocyclic heterocyclic group containing two nitrogen atoms as members of the ring), a salt of the compound, or a prodrug of the compound or the salt, and the drug (b) is a steroid-type anti-inflammatory drug. Therefore, the present invention relates to a therapeutic agent for intractable leukemia.
Nº publicación: AU2014384476A1 15/09/2016
JIANGSU ASCENTAGE BIOMED DEV INC
Disclosed herein are certain indoloquinolone compounds, methods of preparation thereof, pharmaceutical compositions thereof, and uses thereof, such as their uses as ALK inhibitors
Nº publicación: US2016263241A1 15/09/2016
MAYO FOUND FOR MEDICAL EDUCATION AND RES [US]
This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.
Nº publicación: US2016264579A1 15/09/2016
ONO PHARMACEUTICAL CO [JP]
The compound represented by general formula (I) has strong Axl inhibition activity by means of a pyridone ring structure being introduced into a pyrrolo pyrimidine skeleton, and so the result can serve as a treatment agent for Axl-related diseases, for example cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors, renal disease, immune system disorders, and cardiovascular disease.
Nº publicación: EP3066128A1 14/09/2016
SQUIBB BRISTOL MYERS CO [US]
INNATE PHARMA [FR]
Provided are methods for clinical treatment of multiple myeloma using an anti- KIR antibody in combination with an anti-CS 1 antibody.